• 1
    Dent J, Bremner CG, Collen MJ, Haggitt RC, Spechler SJ. Working Party Report to the World Congresses of Gastroenterology, Sydney 1990. Barrett’s oesophagus. J Gastroenterol Hepatol 1991; 6: 122.
  • 2
    Sampliner RE; the Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett’s oesophagus. Am J Gastroenterol 1998; 93: 102832.
    Direct Link:
  • 3
    Nandurkar S, Talley NJ. Surveillance in Barrett’s oesophagus: a need for reassessment? J Gastroenterol Hepatol 1998; 13: 9906.
  • 4
    Hillman LC, Chiragakis L, Clarke AC, et al. Barrett’s oesophagus: macroscopic markers and the prediction of dysplasia and adenocarcinoma. J Gastroenterol Hepatol 2003; 18: 52633.
  • 5
    Falk GW. Barrett’s oesophagus. Gastroenterology 2002; 122: 156991.
  • 6
    Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett’s oesophagus: observational study. BMJ 2000; 321: 12525.
  • 7
    Van Blankenstein M. Barrett’s oesophagus: so what! Dis Esophagus 2002; 15: 14.
  • 8
    Van Der Burgh A, Dees J, Hop WCJ, Van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett’s oesophagus. Gut 1996; 39: 58.
  • 9
    Buttar NS, Wang KK, Sebe TJ, et al. Extent of high-grade dysplasia in Barrett’s oesophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120: 16309.
  • 10
    Stolte M, Vieth M, Schmitz JM, et al. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus. Scand J Gastroenterol 2000; 35: 112530.
  • 11
    Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 8592.
  • 12
    Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s oesophagus: the AGA Chicago workshop. Gastroenterology 2004; 127: 31030.
  • 13
    Weinstein M. The prevention and treatment of dysplasia in gastroesophageal reflux disease: the results and challenges ahead. J Gastroenterol Hepatol 2002; 17: S11324.
  • 14
    Umansky M, Yasui W, Hallak A, et al. Proton pump inhibitors reduce cell cycle anomalies in Barrett's esophagus. Oncogene 2001; 20: 798791.
  • 15
    Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett’s oesophagus and the effects of acid suppression. Gastroenterology 1999; 117: 32735.
  • 16
    Fennerty MB, Triadafilopoulos G. Barrett’s related adenocarcinoma: is chemoprevention a potential option? Am J Gastroenterol 2001; 96: 23025.
    Direct Link:
  • 17
    Peters FTM, Ganesh S, Kuipers EJ, et al. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett oesophagus. Scand J Gastroenterol 2000; 12: 123944.
  • 18
    Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med J Aust 2004; 180: 38791.
  • 19
    El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s oesophagus. Am J Gastroenterol 2004; 99: 187783.
    Direct Link:
  • 20
    Koop H. Gastroesophageal reflux disease and Barrett’s oesophagus. Endoscopy 2002; 34: 97103.
  • 21
    Hofstetter WL, Peters JH, DeMeester TR, et al. Long-term outcome of antireflux surgery in patients with Barrett’s oesophagus. Ann Surg 2001; 234: 5329.
  • 22
    Chen L, Hu C, Gabeury L, et al. Proliferative activity in Barrett’s oesophagus before and after antireflux surgery. Ann Surg 2001; 234: 17280.
  • 23
    Peters JH, Clark GWB, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett’s oesophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108: 81322.
  • 24
    Csendes A, Burdiles P, Braghetto I, Korn O. Adenocarcinoma appearing very late after antireflux surgery for Barrett’s oesophagus: long-term follow-up, review of the literature, and addition of six patients. J Gastrointestinal Surg 2004; 8: 43441.
  • 25
    El-Serag HB, Aguirre T, Kubeler M, Sampliner RE. The length of newly diagnosed Barrett’s oesophagus and prior use of acid suppressive therapy. Aliment Pharmacol Ther 2004; 19: 125560.
  • 26
    Souza RF, Shewmake K, Terada LS, Spechler SJ. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett’s oesophagus. Gastroenterology 2002; 122: 299307.
  • 27
    Feagins LA, Zhang HY, Hormi-Carver K, et al. Acid has antiproliferative effects in nonneoplastic Barrett’s epithelial cells. Am J Gastroenterol 2007; 102: 1020.
    Direct Link:
  • 28
    Zhang HY, Zhang X, Hormi-Carver K, et al. In non-neoplastic Barrett’s epithelial cells, acid exerts antiproliferative effects through activation of the Chk2 pathway. Cancer Res 2007; 67: 85807.
  • 29
    Leedham S, Jankowski J. The evidence base of proton pump inhibitor chemopreventative agents in Barrett’s esophagus – the good, the bad, and the flawed. Am J Gastroenterol 2007; 102: 213.
    Direct Link: